{
  "openalex_id": "W4365513634",
  "doi": "https://doi.org/10.1158/1538-7445.am2023-ct032",
  "title": "Abstract CT032: Trials in progress: a global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma",
  "abstract": "Abstract Background: Patients with cancers driven by BRAF Class II (C II) or C III alterations and/or NRAS mutations are unlikely to benefit from approved BRAF-targeted therapies and have few other treatment options. Exarafenib is a potentially best in class orally available pan-RAF inhibitor optimized for potency &amp; high selectivity. It has differentiated dose-dependent activity across a broad range of cell lines &amp; models driven by BRAF C I (inc. those with acquired resistance to 1st gen RAFi), C II, C III or NRAS alterations. Methods: KN-8701 (NCT04913285) is an ongoing Phase 1 dose escalation &amp; dose expansion study at 35 sites in 7 countries evaluating exarafenib monotherapy in participants (pts) with advanced solid tumors harboring oncogenic BRAF or NRAS alterations. Results: Preliminary results as of 13 Dec 2022 are reported for 52 pts (median age 63, 51.9% male) with a median of 3 prior therapies treated in 6 dose levels. Treated pts included those with solid tumors driven by BRAF C I (38.5%), C II (19.2%), C III (28.8%) alterations or melanoma pts with NRAS mutations (13.5%). Steady state exarafenib exposure (Cmax and AUC) increased dose proportionally. Pathway inhibition &amp; decreases in ctDNA were observed across BRAF classes &amp; tumor types. Dose limiting toxicities observed at the highest dose level were Grade 3 (Gr3) acneiform rash &amp; Gr3 macular rash. The maximum tolerated dose (MTD) was determined to be 300 mg bid. Treatment-related adverse events (TRAEs) (any grade) occurred in 69.2% of pts with 13.5% of pts having Gr ≥3 events. Skin AEs (any grade) were the most common TRAEs observed in 48.1% of pts with 7.7% of pts having Gr ≥ 3 skin events. GI TRAEs occurred in 19.2% pts (Gr 1-2 only), including diarrhea (1 pt, Gr 1). Reversible, asymptomatic Gr 3 increased ALT and/or increased AST AEs in 3 pts were the only non-skin Gr ≥ 3 TRAEs reported in ≥ 2 pts. At therapeutically relevant exposures, there was no cutaneous evidence of paradoxical activation. Of the 34 pts across all dose levels with at least 1 post-baseline tumor assessment, 6 pts (17.6%) had a partial response (5 confirmed at submission date) &amp; 16 pts (47.1%) had stable disease including 8 pts (23.5%) with objective tumor shrinkage (up to 20%). The 6 responders all continue exarafenib therapy (treatment duration up to 12 months) and include 3 pts with BRAF C I alteration-driven cancers (inc. 1 RAFi + MEKi pre-treated melanoma pt) and 1 pt each with BRAF C II, BRAF C III-driven &amp; NRAS-mutation driven cancers. For pts who achieved or confirmed their best response at MTD, the response rate was 33% (4/12) &amp; included responses in pts with BRAF C I, C II, C III, and NRAS mutant tumors. Conclusions: Exarafenib achieves therapeutically meaningful drug exposures and demonstrates promising tolerability &amp; clinical activity in BRAF or NRAS alteration-driven solid tumors. Pt enrollment &amp; exarafenib treatment at 300 mg bid continues. Citation Format: Alexander Spira, Valentina Gambardella, Shumei Kato, Cesar Batista Perez, Meredith Mckean, Maria Gonzalez Cao, Richard Kim, Chris T Chen, Antoine Italiano, Philippe Cassier, Janice Mehnert, Bartosz Chmielowski, Gerri Lee, Paul Severson, Caro Unger, Xiaowei Guan, Richard Williams, Georgina Long. Trials in progress: a global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT032.",
  "authors": [
    {
      "display_name": "Alexander I. Spira",
      "id": "A5044613951",
      "orcid": "https://orcid.org/0000-0003-1303-0447",
      "institutions": [
        {
          "id": "I4210122908",
          "display_name": "Virginia Cancer Specialists",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Alexander Spira"
    },
    {
      "display_name": "Valentina Gambardella",
      "id": "A5043587888",
      "orcid": "https://orcid.org/0000-0001-6081-8830",
      "institutions": [
        {
          "id": "I4210094406",
          "display_name": "Hospital Clínico Universitario de Valencia",
          "country_code": "ES",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Valentina Gambardella"
    },
    {
      "display_name": "Shumei Kato",
      "id": "A5086626483",
      "orcid": "https://orcid.org/0000-0003-1193-1815",
      "institutions": [
        {
          "id": "I36258959",
          "display_name": "University of California, San Diego",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Shumei Kato"
    },
    {
      "display_name": "Cesar Batista Perez",
      "id": "A5015987308",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210135086",
          "display_name": "Tennessee Oncology",
          "country_code": "US",
          "type": "healthcare"
        },
        {
          "id": "I4210100810",
          "display_name": "Sarah Cannon",
          "country_code": "US",
          "type": "facility"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Cesar Batista Perez"
    },
    {
      "display_name": "Meredith McKean",
      "id": "A5002575629",
      "orcid": "https://orcid.org/0000-0003-0944-7418",
      "institutions": [
        {
          "id": "I4210135086",
          "display_name": "Tennessee Oncology",
          "country_code": "US",
          "type": "healthcare"
        },
        {
          "id": "I4210100810",
          "display_name": "Sarah Cannon",
          "country_code": "US",
          "type": "facility"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Meredith Mckean"
    },
    {
      "display_name": "María González Cao",
      "id": "A5110192432",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210096255",
          "display_name": "Hospital Universitario Dexeus",
          "country_code": "ES",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Maria Gonzalez Cao"
    },
    {
      "display_name": "Richard D. Kim",
      "id": "A5045482037",
      "orcid": "https://orcid.org/0000-0002-8448-844X",
      "institutions": [
        {
          "id": "I3019308854",
          "display_name": "Moffitt Cancer Center",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Richard Kim"
    },
    {
      "display_name": "Chris T Chen",
      "id": "A5078754886",
      "orcid": null,
      "institutions": [
        {
          "id": "I1743320",
          "display_name": "Palo Alto University",
          "country_code": "US",
          "type": "education"
        },
        {
          "id": "I97018004",
          "display_name": "Stanford University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Chris T Chen"
    },
    {
      "display_name": "Antoîne Italiano",
      "id": "A5060949051",
      "orcid": "https://orcid.org/0000-0002-8540-5351",
      "institutions": [
        {
          "id": "I4210134409",
          "display_name": "Institut Bergonié",
          "country_code": "FR",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Antoine Italiano"
    },
    {
      "display_name": "Philippe A. Cassier",
      "id": "A5027371764",
      "orcid": "https://orcid.org/0000-0003-3857-1688",
      "institutions": [
        {
          "id": "I4210105738",
          "display_name": "Centre Léon Bérard",
          "country_code": "FR",
          "type": "nonprofit"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Philippe Cassier"
    },
    {
      "display_name": "Janice M. Mehnert",
      "id": "A5113830060",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210086933",
          "display_name": "NYU Langone Health",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Janice Mehnert"
    },
    {
      "display_name": "Bartosz Chmielowski",
      "id": "A5039301683",
      "orcid": "https://orcid.org/0000-0002-2374-3320",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Bartosz Chmielowski"
    },
    {
      "display_name": "Gerri Lee",
      "id": "A5051054603",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Gerri Lee"
    },
    {
      "display_name": "Paul Severson",
      "id": "A5071964860",
      "orcid": "https://orcid.org/0009-0008-6762-6557",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Paul Severson"
    },
    {
      "display_name": "Caro Unger",
      "id": "A5061116259",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Caro Unger"
    },
    {
      "display_name": "Xiaowei Guan",
      "id": "A5063349770",
      "orcid": "https://orcid.org/0000-0003-1393-6214",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Xiaowei Guan"
    },
    {
      "display_name": "Richard T. Williams",
      "id": "A5100708756",
      "orcid": "https://orcid.org/0000-0002-4387-1581",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Richard Williams"
    },
    {
      "display_name": "Georgina V. Long",
      "id": "A5070576000",
      "orcid": "https://orcid.org/0000-0001-8894-3545",
      "institutions": [
        {
          "id": "I129604602",
          "display_name": "The University of Sydney",
          "country_code": "AU",
          "type": "funder"
        },
        {
          "id": "I4210118383",
          "display_name": "Melanoma Institute Australia",
          "country_code": "AU",
          "type": "nonprofit"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Georgina Long"
    }
  ],
  "publication_year": 2023,
  "publication_date": "2023-04-14",
  "type": "article",
  "cited_by_count": 5,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S168522863",
    "display_name": "Cancer Research",
    "issn_l": "0008-5472",
    "issn": [
      "0008-5472",
      "1538-7445"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310320273"
  },
  "volume": "83",
  "issue": "8_Supplement",
  "first_page": "CT032",
  "last_page": "CT032",
  "open_access": {
    "is_oa": false,
    "oa_status": "closed",
    "oa_url": null,
    "any_repository_has_fulltext": false
  },
  "concepts": [
    {
      "id": "C21790070",
      "display_name": "Neuroblastoma RAS viral oncogene homolog",
      "level": 5,
      "score": 0.8757868
    },
    {
      "id": "C2778570526",
      "display_name": "Rash",
      "level": 2,
      "score": 0.7966975
    },
    {
      "id": "C71924100",
      "display_name": "Medicine",
      "level": 0,
      "score": 0.7560326
    },
    {
      "id": "C126322002",
      "display_name": "Internal medicine",
      "level": 1,
      "score": 0.568201
    },
    {
      "id": "C22979827",
      "display_name": "Cmax",
      "level": 3,
      "score": 0.54241997
    },
    {
      "id": "C143998085",
      "display_name": "Oncology",
      "level": 1,
      "score": 0.5100792
    },
    {
      "id": "C197934379",
      "display_name": "Adverse effect",
      "level": 2,
      "score": 0.48187718
    },
    {
      "id": "C2777658100",
      "display_name": "Melanoma",
      "level": 2,
      "score": 0.4773869
    },
    {
      "id": "C57992300",
      "display_name": "Potency",
      "level": 3,
      "score": 0.43508542
    },
    {
      "id": "C121608353",
      "display_name": "Cancer",
      "level": 2,
      "score": 0.39276367
    },
    {
      "id": "C98274493",
      "display_name": "Pharmacology",
      "level": 1,
      "score": 0.39118856
    },
    {
      "id": "C502942594",
      "display_name": "Cancer research",
      "level": 1,
      "score": 0.34726512
    },
    {
      "id": "C112705442",
      "display_name": "Pharmacokinetics",
      "level": 2,
      "score": 0.24647984
    },
    {
      "id": "C2781187634",
      "display_name": "KRAS",
      "level": 4,
      "score": 0.20112038
    },
    {
      "id": "C86803240",
      "display_name": "Biology",
      "level": 0,
      "score": 0.13720009
    },
    {
      "id": "C202751555",
      "display_name": "In vitro",
      "level": 2,
      "score": 0.13240123
    },
    {
      "id": "C54355233",
      "display_name": "Genetics",
      "level": 1,
      "score": 0.08527705
    },
    {
      "id": "C526805850",
      "display_name": "Colorectal cancer",
      "level": 3,
      "score": 0.0
    }
  ],
  "topics": [
    {
      "id": "T11533",
      "display_name": "Melanoma and MAPK Pathways",
      "score": 0.9986
    },
    {
      "id": "T10211",
      "display_name": "Computational Drug Discovery Methods",
      "score": 0.9891
    },
    {
      "id": "T10274",
      "display_name": "Synthesis and biological activity",
      "score": 0.9707
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.1158/1538-7445.am2023-ct032",
  "pdf_url": null,
  "retrieved_date": "2025-07-30T15:28:52.063601",
  "source_database": "OpenAlex"
}